JP2015183006A - 心疾患を治療するための吸入式医薬組成物及びその調製法 - Google Patents
心疾患を治療するための吸入式医薬組成物及びその調製法 Download PDFInfo
- Publication number
- JP2015183006A JP2015183006A JP2015060834A JP2015060834A JP2015183006A JP 2015183006 A JP2015183006 A JP 2015183006A JP 2015060834 A JP2015060834 A JP 2015060834A JP 2015060834 A JP2015060834 A JP 2015060834A JP 2015183006 A JP2015183006 A JP 2015183006A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- inhalation
- type pharmaceutical
- gas
- heart disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 132
- 208000019622 heart disease Diseases 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 title claims description 48
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 239000007789 gas Substances 0.000 claims abstract description 157
- 239000001257 hydrogen Substances 0.000 claims abstract description 104
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 104
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 98
- 239000003814 drug Substances 0.000 claims abstract description 49
- 229940079593 drug Drugs 0.000 claims abstract description 45
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000001301 oxygen Substances 0.000 claims abstract description 38
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 38
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims abstract description 26
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims abstract description 14
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims abstract description 13
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims abstract description 13
- 229960002274 atenolol Drugs 0.000 claims abstract description 13
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960004195 carvedilol Drugs 0.000 claims abstract description 13
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims abstract description 13
- 229960003009 clopidogrel Drugs 0.000 claims abstract description 13
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims abstract description 13
- 229960004166 diltiazem Drugs 0.000 claims abstract description 13
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 claims abstract description 13
- 229960004255 nadolol Drugs 0.000 claims abstract description 13
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960002497 nicorandil Drugs 0.000 claims abstract description 13
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960001597 nifedipine Drugs 0.000 claims abstract description 13
- 229960003712 propranolol Drugs 0.000 claims abstract description 13
- 229960001722 verapamil Drugs 0.000 claims abstract description 13
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical group CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims abstract description 12
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 6
- 239000011261 inert gas Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 15
- 239000000006 Nitroglycerin Substances 0.000 claims description 12
- YWXYYJSYQOXTPL-JGWLITMVSA-N [(3r,3ar,6s,6as)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-JGWLITMVSA-N 0.000 claims description 12
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 10
- 238000005868 electrolysis reaction Methods 0.000 claims description 7
- 230000008016 vaporization Effects 0.000 claims description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 16
- 238000000889 atomisation Methods 0.000 abstract description 10
- 150000003254 radicals Chemical class 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 239000007788 liquid Substances 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 230000008020 evaporation Effects 0.000 abstract 1
- 238000001704 evaporation Methods 0.000 abstract 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 abstract 1
- 229960000201 isosorbide dinitrate Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 10
- 208000029078 coronary artery disease Diseases 0.000 description 6
- 238000010586 diagram Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000026758 coronary atherosclerosis Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0085—Inhalators using ultrasonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
- A61M11/042—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical
- A61M11/044—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical with electrodes immersed in the liquid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
- A61M11/045—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters using another liquid as heat exchanger, e.g. bain-marie
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3693—General characteristics of the apparatus related to heating or cooling by mechanical waves, e.g. ultrasonic
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Abstract
【解決手段】第1ガスが水素を含み、吸入式医薬組成物中の水素のガス体積濃度が2〜96%であり、霧化薬がアセチルサリチル酸、クロピドグレル、プロプラノロール、アテノロール、ナドロール、カルベジロール、ニフェジピン、ジルチアゼム、ベラパミル、硝酸イソソルビド、ニコランジル、ニトログリセリン又はそれらの任意の組み合わせである吸入式医薬組成物。第2ガスとして空気、水蒸気、不活性ガス、酸素又はそれの組み合せから選択されるガスを含む吸入式医薬組成物。
【効果】吸入式医薬組成物は、水素の使用により患者の体内の有害なラジカルを除去し、一方、霧化薬を使用することによって患者における薬の吸収効果を増加させ、同時に、少量の気化医薬液の使用のために、使用者への副作用が間接的に減少し得る。
【選択図】なし
Description
1.発明の分野
本発明は、吸入式医薬組成物及びその調製法に関し、より詳細には、心疾患の治療に使用される吸入式医薬組成物及びその調製法に関する。
最近、人々の生活水準の継続的な改善によって、生活及び食事の習慣は徐々に西洋化している。それ故、心疾患の患者数は実質的に増加しており、心疾患は上位10位の人の死亡原因のうちの1つに位置している。同時に、心疾患発症の平均年齢は徐々に低下しているので、心疾患は人間の健康にとって深刻な脅威となっている。
(S1)第1ガスを調製する工程であって、第1ガスは水素を含む、工程;
(S2)薬液を霧化して霧化薬を生成する工程であって、霧化薬はアセチルサリチル酸、クロピドグレル、プロプラノロール、アテノロール、ナドロール、カルベジロール、ニフェジピン、ジルチアゼム、ベラパミル、硝酸イソソルビド、ニコランジル、ニトログリセリン又はそれらの任意の組み合わせである、工程;及び
(S3)第1ガスと霧化薬とを混合して吸入式医薬組成物を生成する工程であって、吸入式医薬組成物中の水素のガス体積濃度は2〜96%の間である、工程。
(S21)第1ガスを調製する工程であって、第1ガスは水素を含む、工程;
(S22)薬液を霧化して霧化薬を生成する工程であって、霧化薬はアセチルサリチル酸、クロピドグレル、プロプラノロール、アテノロール、ナドロール、カルベジロール、ニフェジピン、ジルチアゼム、ベラパミル、硝酸イソソルビド、ニコランジル、ニトログリセリン又はそれらの任意の組み合わせである、工程;
(S23)第2ガスを調製する工程;及び
(S24)第1ガス、第2ガス及び霧化薬を混合して吸入式医薬組成物を生成する工程。本実施形態では、心疾患を治療するための吸入式医薬組成物中の水素のガス体積濃度は、第2ガスを添加することによって低減され得る。
(S1)第1ガスを調製する工程であって、第1ガスは水素を含む、工程;
(S2)薬液を霧化して霧化薬を生成する工程であって、霧化薬はアセチルサリチル酸、クロピドグレル、プロプラノロール、アテノロール、ナドロール、カルベジロール、ニフェジピン、ジルチアゼム、ベラパミル、硝酸イソソルビド、ニコランジル、ニトログリセリン又はそれらの任意の組み合わせである、工程;及び
(S3)第1ガスと霧化薬とを混合して吸入式医薬組成物を生成する工程であって、吸入式医薬組成物中の水素のガス体積濃度は2〜96%の間である、工程。
(S21)第1ガスを調製する工程であって、第1ガスは水素を含む、工程;
(S22)薬液を霧化して霧化薬を生成する工程であって、霧化薬はアセチルサリチル酸、クロピドグレル、プロプラノロール、アテノロール、ナドロール、カルベジロール、ニフェジピン、ジルチアゼム、ベラパミル、硝酸イソソルビド、ニコランジル、ニトログリセリン又はそれらの任意の組み合わせである、工程;
(S23)第2ガスを調製する工程;及び
(S24)第1ガス、第2ガス及び霧化薬を混合して吸入式医薬組成物を生成する工程。
Claims (20)
- 第1ガス及び霧化薬を含む心疾患を治療するための吸入式医薬組成物であって、前記第1ガスは水素を含み、前記吸入式医薬組成物中の前記水素のガス体積濃度は2〜96%の間であり、前記霧化薬はアセチルサリチル酸、クロピドグレル、プロプラノロール、アテノロール、ナドロール、カルベジロール、ニフェジピン、ジルチアゼム、ベラパミル、硝酸イソソルビド、ニコランジル、ニトログリセリン又はそれらの任意の組み合わせである、心疾患を治療するための吸入式医薬組成物。
- 請求項1に記載の心疾患を治療するための吸入式医薬組成物であって、前記第1ガスはさらに酸素を含む、心疾患を治療するための吸入式医薬組成物。
- 請求項2に記載の心疾患を治療するための吸入式医薬組成物であって、前記第1ガスは水の電気分解から生成される水素と酸素のガス混合物であり、前記水素と前記酸素の体積比は2:1である、心疾患を治療するための吸入式医薬組成物。
- 請求項2に記載の心疾患を治療するための吸入式医薬組成物であって、さらに前記吸入式医薬組成物中の前記水素のガス体積濃度を減少させるために第2ガスを含み、該第2ガスは空気、水蒸気、不活性ガス、酸素又はそれらの任意の組み合わせを含む群から選択されるガスである、心疾患を治療するための吸入式医薬組成物。
- 請求項1に記載の心疾患を治療するための吸入式医薬組成物であって、前記吸入式医薬組成物中の前記水素のガス体積濃度は2〜66.66%の間である、心疾患を治療するための吸入式医薬組成物。
- 請求項1に記載の心疾患を治療するための吸入式医薬組成物であって、前記吸入式医薬組成物中の前記水素のガス体積濃度は4.7〜66.66%の間である、心疾患を治療するための吸入式医薬組成物。
- 請求項1に記載の心疾患を治療するための吸入式医薬組成物であって、前記吸入式医薬組成物中の前記水素のガス体積濃度は60〜66.66%の間である、心疾患を治療するための吸入式医薬組成物。
- 請求項1に記載の心疾患を治療するための吸入式医薬組成物であって、前記吸入式医薬組成物中の前記水素のガス体積濃度は66.66%よりも大きい、心疾患を治療するための吸入式医薬組成物。
- 請求項1に記載の心疾患を治療するための吸入式医薬組成物であって、前記霧化薬は薬液を霧化又は気化させることによって生成される、心疾患を治療するための吸入式医薬組成物。
- 請求項9に記載の心疾患を治療するための吸入式医薬組成物であって、前記薬液はアセチルサリチル酸、クロピドグレル、プロプラノロール、アテノロール、ナドロール、カルベジロール、ニフェジピン、ジルチアゼム、ベラパミル、硝酸イソソルビド、ニコランジル、ニトログリセリン又はそれらの任意の組み合わせである、心疾患を治療するための吸入式医薬組成物。
- 心疾患を治療するための吸入式医薬組成物の調製法であって、それは以下の工程:
(S1)第1ガスを調製する工程であって、前記第1ガスは水素を含む、工程;
(S2)薬液を霧化して霧化薬を生成する工程であって、前記霧化薬はアセチルサリチル酸、クロピドグレル、プロプラノロール、アテノロール、ナドロール、カルベジロール、ニフェジピン、ジルチアゼム、ベラパミル、硝酸イソソルビド、ニコランジル、ニトログリセリン又はそれらの任意の組み合わせである、工程;及び
(S3)前記第1ガスと前記霧化薬とを混合して前記吸入式医薬組成物を生成する工程であって、前記吸入式医薬組成物中の前記水素のガス体積濃度は2〜96%の間である、工程、
を含む、心疾患を治療するための吸入式医薬組成物の調製法。 - 請求項11に記載の心疾患を治療するための吸入式医薬組成物の調製法であって、さらに前記工程(S2)の後に以下の工程:
(S23)第2ガスを調製する工程、
を含む、心疾患を治療するための吸入式医薬組成物の調製法。 - 請求項12に記載の心疾患を治療するための吸入式医薬組成物の調製法であって、前記工程(S3)では、前記吸入式医薬組成物は前記第1ガス、前記第2ガス及び前記霧化薬を混合することから生成される、心疾患を治療するための吸入式医薬組成物の調製法。
- 請求項12に記載の心疾患を治療するための吸入式医薬組成物の調製法であって、前記第2ガスは前記吸入式医薬組成物中の前記水素のガス体積濃度を減少させるために使用される、心疾患を治療するための吸入式医薬組成物の調製法。
- 請求項12に記載の心疾患を治療するための吸入式医薬組成物の調製法であって、前記第2ガスは空気、水蒸気、不活性ガス、酸素又はそれらの任意の組み合わせを含む群から選択されるガスである、心疾患を治療するための吸入式医薬組成物の調製法。
- 請求項11に記載の心疾患を治療するための吸入式医薬組成物の調製法であって、前記工程(S1)では、前記第1ガスは水を電気分解することによって生成され、前記第1ガスは水素と酸素のガス混合物を含み、前記水素と前記酸素の体積比は2:1である、心疾患を治療するための吸入式医薬組成物の調製法。
- 請求項11に記載の心疾患を治療するための吸入式医薬組成物の調製法であって、前記吸入式医薬組成物中の前記水素のガス体積濃度は2〜66.66%の間である、心疾患を治療するための吸入式医薬組成物の調製法。
- 請求項11に記載の心疾患を治療するための吸入式医薬組成物の調製法であって、前記吸入式医薬組成物中の前記水素のガス体積濃度は4.7〜66.66%の間である、心疾患を治療するための吸入式医薬組成物の調製法。
- 請求項11に記載の心疾患を治療するための吸入式医薬組成物の調製法であって、前記吸入式医薬組成物中の前記水素のガス体積濃度は60〜66.66%の間である、心疾患を治療するための吸入式医薬組成物の調製法。
- 請求項11に記載の心疾患を治療するための吸入式医薬組成物の調製法であって、前記吸入式医薬組成物中の前記水素のガス体積濃度は66.66%よりも大きい、心疾患を治療するための吸入式医薬組成物の調製法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW103110985 | 2014-03-25 | ||
TW103110985A TWI590837B (zh) | 2014-03-25 | 2014-03-25 | 一種用於治療心臟病之吸入式醫藥組成物及其備製方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2015183006A true JP2015183006A (ja) | 2015-10-22 |
Family
ID=54067009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015060834A Pending JP2015183006A (ja) | 2014-03-25 | 2015-03-24 | 心疾患を治療するための吸入式医薬組成物及びその調製法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9375396B2 (ja) |
JP (1) | JP2015183006A (ja) |
KR (1) | KR20150111328A (ja) |
CN (1) | CN104940223A (ja) |
DE (1) | DE102015104360A1 (ja) |
TW (1) | TWI590837B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015205863A (ja) * | 2014-04-18 | 2015-11-19 | リン, シン−ユンLin, Hsin−Yung | 関節炎を治療するための吸入式医薬組成物及びその調製法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6666701B2 (ja) * | 2015-12-01 | 2020-03-18 | 日本光電工業株式会社 | 水素ガス供給装置 |
CN113599387B (zh) * | 2021-09-15 | 2023-03-28 | 山东中医药大学附属医院 | 一种复方制剂及其在制备治疗心绞痛药物中的用途 |
CN117899106A (zh) * | 2022-10-11 | 2024-04-19 | 上海氢医医疗科技有限公司 | 氢气吸入干预早产儿促进发育 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003018058A1 (fr) * | 2001-08-22 | 2003-03-06 | Mitsuhiro Yokota | Inhibiteur d'apoptose de cellules myocardiques |
JP2010504171A (ja) * | 2006-09-20 | 2010-02-12 | ネクスト セーフティ インコーポレイテッド | 吸入を通した薬物供給の方法およびシステム |
JP2012520890A (ja) * | 2009-03-18 | 2012-09-10 | インカーダ セラピューティクス, インコーポレイテッド | 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法 |
WO2013183448A1 (ja) * | 2012-06-04 | 2013-12-12 | ミズ株式会社 | 生体用高濃度水素ガス供給装置 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0921807T3 (da) * | 1996-08-27 | 2004-03-15 | Messer Griesheim Gmbh | Hydrogenholdigt lægemiddel |
DE19734279A1 (de) * | 1997-08-07 | 1999-02-11 | Messer Griesheim Gmbh | Wasserstoffhaltiges Medikament |
JP6058888B2 (ja) * | 2008-07-24 | 2017-01-11 | ゲノ エルエルシー | 患者における心臓の病気の診断及び治療方法 |
GB0921481D0 (en) | 2009-12-08 | 2010-01-20 | Vectura Ltd | Process and product |
-
2014
- 2014-03-25 TW TW103110985A patent/TWI590837B/zh active
- 2014-07-16 CN CN201410337827.1A patent/CN104940223A/zh active Pending
-
2015
- 2015-03-20 US US14/664,491 patent/US9375396B2/en active Active
- 2015-03-24 JP JP2015060834A patent/JP2015183006A/ja active Pending
- 2015-03-24 DE DE102015104360.2A patent/DE102015104360A1/de not_active Withdrawn
- 2015-03-25 KR KR1020150041704A patent/KR20150111328A/ko not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003018058A1 (fr) * | 2001-08-22 | 2003-03-06 | Mitsuhiro Yokota | Inhibiteur d'apoptose de cellules myocardiques |
JP2010504171A (ja) * | 2006-09-20 | 2010-02-12 | ネクスト セーフティ インコーポレイテッド | 吸入を通した薬物供給の方法およびシステム |
JP2012520890A (ja) * | 2009-03-18 | 2012-09-10 | インカーダ セラピューティクス, インコーポレイテッド | 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法 |
WO2013183448A1 (ja) * | 2012-06-04 | 2013-12-12 | ミズ株式会社 | 生体用高濃度水素ガス供給装置 |
Non-Patent Citations (5)
Title |
---|
MEDICAL GASES, vol. 15, no. 1, JPN6016010834, 2013, pages 42 - 48, ISSN: 0003282019 * |
ファーマシスト・ぷらす, JPN6016010836, 2013, pages 4 - 9, ISSN: 0003282021 * |
医学書院 医学大辞典, JPN6016002807, 1 March 2003 (2003-03-01), pages 565, ISSN: 0003282022 * |
改訂 医用超音波機器ハンドブック, JPN6016002808, 20 January 1997 (1997-01-20), pages 177 - 178, ISSN: 0003282023 * |
日薬理誌, vol. 108, JPN6016010835, 1996, pages 195 - 202, ISSN: 0003282020 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015205863A (ja) * | 2014-04-18 | 2015-11-19 | リン, シン−ユンLin, Hsin−Yung | 関節炎を治療するための吸入式医薬組成物及びその調製法 |
Also Published As
Publication number | Publication date |
---|---|
TWI590837B (zh) | 2017-07-11 |
TW201536359A (zh) | 2015-10-01 |
KR20150111328A (ko) | 2015-10-05 |
US20150272868A1 (en) | 2015-10-01 |
CN104940223A (zh) | 2015-09-30 |
US9375396B2 (en) | 2016-06-28 |
DE102015104360A1 (de) | 2015-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015183005A (ja) | アルツハイマー病を治療するための吸入式医薬組成物及びその調製法 | |
US9763946B2 (en) | Inhalation-type pharmaceutical composition for the treatment of lung cancer and preparation method thereof | |
JP2015183006A (ja) | 心疾患を治療するための吸入式医薬組成物及びその調製法 | |
JP2015205864A (ja) | 痛風を治療するための吸入式医薬組成物及びその調製法 | |
JP2015183004A (ja) | パーキンソン病を治療するための吸入式医薬組成物及びその調製法 | |
US9827193B2 (en) | Inhalation-type pharmaceutical composition for the treatment of hypertension and preparation method thereof | |
JP2015205863A (ja) | 関節炎を治療するための吸入式医薬組成物及びその調製法 | |
JP2015205867A (ja) | 糖尿病の治療用の吸入型医薬組成物およびその調製方法 | |
JP2015205865A (ja) | 腎疾患の治療用の吸入型医薬組成物およびその調製方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150724 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160318 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160329 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160629 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160826 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160909 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160928 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170106 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170214 |